GW professor awarded grant to study new methods of early breast cancer detection

October 04, 2012

WASHINGTON (Oct. 04) - Today, patients with precancerous lesions, or early-stage breast cancer are usually diagnosed after a mammography screening. This method of detection can lead to false-positives and overtreatment, since mammography cannot determine whether pre-cancerous cells will actually turn into breast cancer. This may all change after Sidney Fu, M.D., professor of medicine at the George Washington School of Medicine and Health Sciences (SMHS), completes his study of early breast cancer detection using novel small RNA (microRNA or miRNA) biomarkers. Fu, who received a two-year, $362,060 grant from the National Cancer Institute to do this research, hopes to develop a blood test to determine with greater precision whether a patient carries cells that will eventually turn into breast cancer. This test could save women all around the world from unnecessary trauma and stress from chemotherapy, radiation, and surgery.

Breast cancer generally develops in the cells surrounding the milk-producing breast ducts. Somehow, either through internal or environmental factors, those cells gradually change in a patient who may develop breast cancer. Initially, cells will just accumulate. At this point, they are normal cells, which are called hyperplasia. If the cells continue to progress, they then become abnormal and enter into the Atypical Ductal Hyperplasia (ADH) stage. At the ADH stage, cells look abnormal under the microscope, but they are not cancer cells. If cells continue to progress into the Ductal Carcinoma In Situ (DCIS) stage (the most common type of non-invasive breast cancer), the cells then become cancer cells. Unfortunately, women who are diagnosed with DCIS have a higher risk of developing invasive breast cancer and surgery, radiation or a mastectomy to remove DCIS has become standard treatment. However, there is no proven way to predict which women diagnosed with DCIS will eventually develop invasive breast cancer over the years, or if they never will. With Fu's research, novel biomarkers may be discovered to help physicians determine whether or not a patient diagnosed with DCIS should be treated rigorously or with simple follow-ups.

In less than a decade, miRNA has become one of the most important set of regulatory molecules in the body. Because the deregulation of these small RNAs are associated with cancer initiation and development, and because they circulate stably in blood, they have great potential as diagnostic and/or prognostic biomarkers for cancer and other diseases. This led Fu to believe that by studying the role of miRNA in early stage breast cancer, he could find novel biomarkers that could tell him whether or not cells will turn cancerous.

"If we can identify the miRNA signatures in DCIS, which can be used to differentiate between patients whose cells may eventually develop into invasive breast cancer and those patients whose cells will never develop into cancer, we would be able to eliminate unnecessary surgery, and/or chemotherapy and radiation therapy for those patients who will not benefit," said Fu.

This research could help develop new methods for the detection of early breast lesions. With a simple blood test, physicians would be able to use the information to guide their clinical practice, said Fu.
To arrange an interview with Dr. Fu, please contact Lisa Anderson at 202-994-3121 or

About the School of Medicine and Health Sciences

Founded in 1825, the GW School of Medicine and Health Sciences (SMHS) was the first medical school in the nation's capital and is the 11th oldest in the country. Working together in our nation's capital, with integrity and resolve, the GW SMHS is committed to improving the health and well-being of our local, national and global communities.

George Washington University

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to